Molecular selection treatment on lung cancer

Cancer and Chemotherapy Reviews

Volumn 4, Issue 1, 2009, Pages 44-51

  Garrido, Pilar ^a   Abad, María Fernández ^a   Olmedo, Ma Eugenia ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Chemotherapy; Molecular selection; NSCLC; Pharmacogenetics; Pharmacogenomics; Targeted therapies

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; PHARMACOGENOMICS; PROGNOSIS; RASH;

EID: 77952492548     PISSN: 1885740X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. American Cancer Society: Cancer Statistics 2008. http://www.cancer.org/ docroot/STT/stt_0.asp
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced NSCLC. N Engl J Med. 2002;346:92-8.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for NSCLC. N Engl J Med. 2006;355:2542-50.
4. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced NSCLC: The TAX 326 study group. J Clin Oncol. 2003;21:3016-24.
5. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in NSCLC. Clin Cancer Res. 2002;8:2286-91.
6. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in NSCLC and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91.
7. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in NSCLC. J Clin Oncol. 2007;25:2747-54.
8. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced NSCLC patients. Clin Cancer Res. 2004;10:1318-25.
9. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in NSCLC. J Clin Oncol. 2006;24:4731-7.
10. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced NSCLC. J Clin Oncol. 2007;25:2741-6.
11. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004;13:2443-9.
12. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol. 2008;26:3543-51.
13. Peterson P, Park K, Fossella FV, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced NSCLC. 12th World Conference on Lung Cancer. 2007; P2-328 [abstract].
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated NSCLC. N Engl J Med. 2005;353:123-32.
15. Clark GM, Zborowski D, Santabárbara P, et al. Smoking history is more predictive of survival benefit from erlotinib for patients with NSCLC than EGFR expression. J Clin Oncol. 2005; 23:374s.
16. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the EGFR tyrosine kinase, in symptomatic patients with NSCLC: A randomized trial. JAMA. 2003;290:2149.
17. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced NSCLC. J Clin Oncol. 2003;21:2237-46.
18. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced NSCLC: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-37.
19. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Gefitinib (marketed as Iressa) Information. FDA Alert. 2005. Available at http://www.fda.gov/cder/drug/infopage/gefitinib/default.htm.
20. Douillard JY, Kim ES, Hirsh V, et al. Phase III randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic NSCLC who have previously received platinum-based chemotherapy (INTEREST). Eur J Cancer. 2007;5:2.
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the EGFR underlying responsiveness of NSCLC to gefitinib. N Engl J Med. 2004;350:2129-39.
22. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500.
23. Wheatley-Price P, Shepherd FA. EGFR inhibitors in the treatment lung cancer: Reality and hopes. Curr Opin Oncol. 2008;20: 162-75.
24. Cappuzzo F, Hirsch FR, Rossi E, et al. EGFR gene and protein and gefitinib sensitivity in NSCLC. J Natl Cancer Inst. 2005;97:643-55.
25. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to EGFR antagonists in NSCLC. J Clin Oncol. 2007;25: 587-95.
26. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the EGFR gene predict prolonged survival after gefitinib treatment in patients with NSCLC with postoperative recurrence. J Clin Oncol. 2005;24:2513-20.
27. Paz-Ares L, Sanchez JM, García-Velasco A, et al. A prospective phase II trial of erlotinib in advanced NSCLC patients with mutations in the tyrosine kinase domain of the EGFR. J Clin Oncol. 2006;24(Suppl 18s):7020a.
28. Inoue A, Suzuki T, Fukuhara T. et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced NSCLC with EGFR gene mutations. J Clin Oncol. 2006;24: 3340-6.
29. Sequist LV, Martins GM, Spigel D, et al: First-line gefitinib in patients with advanced NSCLC harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442-9.
30. Mok T, Yi-Long Wu, Thongprasert S, et al. Phase III, randomized, open label, first-line study gefitinib versus carboplatin/paclitaxel in clinically selected with advanced NSCLC. Ann Oncol. 2008;19: LBA2.
31. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26:1472-8.
32. Hirsch FR, Varela-García M, McCoy J, et al. Increased EGFR gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A SWOG study. J Clin Oncol. 2005; 23:6838-45.
33. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of NSCLC to gefitinib. N Engl J Med. 2005;352:786-92.
34. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-43.
35. Aviel-Ronen S, Blackhall FH, Shepherd FA, et al. K-ras mutations in NSCLC: A review. Clin Lung Cancer. 2006;8:30-8.
36. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.